Introduction
Ahi-1 (Abelson helper integration site 1) is a recently identified gene that is commonly activated by provirus insertional mutagenesis in various murine leukemias and lymphomas. [1] [2] [3] [4] The murine Ahi-1 gene encodes a unique protein with multiple SH3 binding sites, an SH3 domain and multiple WD40-repeat domains, all of which are known to be important mediators of protein-protein interactions, suggesting that the normal Ahi-1 protein has novel signaling activities and that its deregulation could affect several important cellular signaling pathways. Interestingly, the conserved human homolog (AHI-1) contains an additional coiled-coil domain in its N-terminal region, which is entirely missing from the Ahi-1 proteins of both mouse and rat. Both murine and human Ahi-1/AHI-1 genes encode at least three isoforms and thus this gene is also subject to alternative splicing in normal cells. 1 Involvement of Ahi-1 in leukemogenesis is suggested by the high frequency of Ahi-1 mutations seen in certain virus-induced murine leukemias and lymphomas. 1 Murine pre-B-and T-cell leukemic cells with insertional mutations in Ahi-1 show both increased expression of Ahi-1 and expression of truncated Ahi-1/viral-fused transcripts, including splice variants in which the SH3 domain is deleted. 1 We have recently demonstrated that Ahi-1/AHI-1 expression is regulated at multiple stages of hematopoiesis in a manner that is highly conserved between mouse and humans. 5 Ahi-1/AHI-1 is expressed at its highest level in the most primitive hematopoietic cells and is then rapidly downregulated as the cells begin to differentiate. Interestingly, marked deregulation of AHI-1 expression is seen in a broad spectrum of human leukemic cell lines, particularly in the cutaneous T-cell lymphoma cell (CTCL) lines, Hut78, derived from the blood of a patient with Sezary syndrome (SS), and Hut102, derived from blood of a patient with mycosis fungoides (MF), where increases in AHI-1 transcripts of 40-fold are seen. In addition, AHI-1 transcript levels are found to be significantly increased in a chronic myeloid leukemia (CML) cell line (K562) and in primary leukemic cells with Philadelphia chromosome-positive (Ph þ ), but not Ph À leukemias, especially in highly enriched leukemic stem cells from patients with CML. 5 These results suggest that downregulation of Ahi-1/AHI-1 expression is an important conserved step in primitive normal hematopoietic cell differentiation and that perturbations in AHI-1 expression may contribute to the development of specific types of human leukemia and lymphomas.
SS is a leukemic variant of human CTCL characterized by erythroderma, generalized lymphadenopathy, and the presence of neoplastic Sezary cells in the skin, lymph nodes and peripheral blood. [6] [7] [8] SS is also generally considered to be a leukemic variant of the more common human CTCL, MF. 6 Both SS and MF account for 2-3% of all lymphomas and 470% of all CTCLs. SS has a poor prognosis with an estimated 5-year survival of 15%. 9 Therefore, the development of Sezary cells denotes a poor prognosis and the results of various treatments for SS are generally disappointing. Little is known about the molecular nature of the leukemic cells involved in SS and MF. Studies of SS have demonstrated aberrations in signaling by signal transducers and activators of transcription family proteins, [10] [11] [12] [13] overexpression of Jun B 14 and diminished expression of the transforming growth factor-b receptor, 15, 16 and Fas. 17 Other studies have pointed to the presence of chromosomal alterations, indicating genomic instability, 18, 19 including p53 tumor suppressor gene mutations. 8, 20 Our recent findings of marked deregulation of AHI-1 in human CTCL cells suggest AHI-1 may play an oncogenic role in human CTCL.
In this study, we targeted expression of AHI-1 in Hut78 cells using retroviral-mediated RNA interference (RNAi). We found that suppression of AHI-1 specifically inhibited AHI-1 expression and then reduced the autocrine production of IL-2, IL-4 and tumor necrosis factor-alpha (TNFa) in transduced Hut78 cells. Stable inhibition of AHI-1 in Hut78 cells further normalized its transforming activity in vitro and in vivo. Aberrant expression of AHI-1, particularly shorter isoforms, was also found in leukemic Sezary cells from SS patients. These findings reinforce the concept that alterations in the expression of AHI-1 may be important in the development of SS.
Materials and methods

Retroviral vector and virus production
The RPG vector was constructed based on the RVH1 vector as described. 21 The cytomegalovirus promoter was replaced with the phosphogluco kinase (PGK) promoter, and the human CD4 gene was replaced with an enhanced green fluorescent protein as a selection marker. The human H1 promoter was maintained upstream of the PGK promoter. The oligonucleotides encoding the AHI-1 small interfering RNAs (siRNA) that inhibited AHI-1 expression (AHI-sh4) were 5 0 -GATCCCCGTGATGATCCCGA CACTATTTCAAGAGAATAGTGTCGGGATCATCACTTTTTA-3 0 and 5 0 -AGCTTAAAAAGTGATGATCCCGACACTATTCTCTTGA AATAGTGTCGGGATCATCACGGG-3 0 . These were annealed and ligated downstream of the H1 promoter, and cloned into the pSUPER plasmid. 22, 23 These pSUPER-AHI-1 short hairpin (shRNA) oligos were digested with XhoI and EcoRI and cloned into the RPG vector. Constructs were verified by DNA sequencing. Helper-free virus was obtained by transfecting amphotropic Phoenix packaging cells 24 cultured in Dulbecco's modified Eagle's medium (DMEM) plus 10% fetal calf serum (FCS) using the calcium-phosphate precipitation method as described. 25 Cell culture and retroviral transduction of Hut78 cells 
Quantitative real-time RT-PCR analyses (Q-RT-PCR)
Total RNA was extracted from aliquots of cells using the Absolutely RNA Microprep kit (Stratagene, La Jolla, CA, USA) or TRIzol (Invitrogen, Burlington, Ontario, Canada) and RT reactions were performed as described. 27 Real-time PCR was performed using 25 ml of 2 Â SYBR Green PCR Master Mix 0 . Specific primers to detect all AHI-1 isoforms and optimal conditions for the amplification of these gene products and for normalization of the C t values of the gene of interest to that of GAPDH were described previously.
5,28
Northern blot analysis Twenty microgram of total RNA isolated from transduced Hut78 cells was separated on 1.2% ready-to-use seakem gold agarose gels (Cambrex Bio Science, Rockland, ME, USA), transferred onto nylon membranes and hybridized with a 2.0 kb human AHI-1 cDNA probe. The membrane was then stripped and probed with a human actin probe as described previously. 5 
Antibody production
One Ahi-1-glutathione S-tranferase (GST) fusion protein was constructed by in-frame cloning of the C-terminal region of Ahi-1 cDNA into a pGEX4T-1 vector (amino acids 961-1020 with a high homology to human AHI-1 sequences). The Ahi-1 fusion protein was then purified and injected into rabbits. Serum was collected and the titers of antibody were determined by enzymelinked immunisorbent assay (ELISA) and Western blot analysis. The antibody was further purified by affinity chromatography as described previously. 29 
Western blot analyses
Cells were lysed in phosphorylation solubilization buffer as described previously. 28 Protein lysates were then separated on NuPAGE Novex bis-tris gels (Invitrogen) and the filters were probed with a polyclonal anti-Ahi-1 antibody (C-terminal) or a polyclonal N-terminal AHI-1 antibody, IMX-3395 (IMGENEX, San Diego, CA, USA). Western blot analysis was also performed using an anti-TNFa antibody (H-156, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a monoclonal human anti-actin antibody (Sigma, Saint Louis, MO, USA). Relative expression levels of AHI-1 and TNFa were normalized to expression levels of human actin after quantification with ImageQuant software.
CFC assay
Colony-forming cell (CFC) assays were performed in FCScontaining methylcellulose cultures (H4230, StemCell Technologies)720 U/ml human IL-2, 5 ng/ml human IL-4 and 5 ng/ml human TNFa (BioSource, Camarillo, CA, USA). Colony counts were performed, using standard scoring criteria, on the basis of the ability to produce colonies containing a minimum of 20 cells after 12-14 days of incubation. 30 
ELISA
Transduced Hut78 cells were incubated at 5 Â 10 6 /ml for 48 h and TNFa levels in supernatants were then measured with a commercially available ELISA kit (R&D system, Minneapolis, MN, USA).
Animals
Non-obese diabetic (NOD)/severe-combined immunodeficiency (SCID)-b2 microglobulin (b2m) À/À mice 31 were bred and maintained in microisolator cages provided with autoclaved food and water. Mice at 8-10 weeks of age were injected subcutaneously with 2 Â 10 7 transduced Hut78 cells. Mice were monitored for local tumor formation.
Results
Stable suppression of AHI-1 expression decreases autocrine production of cytokines in Hut78 cells
To investigate directly whether deregulated expression of AHI-1 in human leukemic cells contributes to their transformed properties, knockdown of AHI-1 expression in Hut78 cells, a cell line that shows highly deregulated AHI-1 expression, 5 was performed using retroviral-mediated RNAi. 22, 23 Hut78 cells are characterized by several interesting transforming phenotypes, including growth factor independence, autocrine production of IL-2, IL-4, TNFa and interferon-g (IFN-g), and induction of tumors in mice. [32] [33] [34] In order to suppress AHI-1 and its isoforms efficiently and therefore obtain a biologically significant effect, a vector-based transfer strategy was employed to achieve lasting transcript suppression. Nine 19 nt AHI-1 target sequences, derived from different regions of AHI-1 and that produce specific short hairpin transcripts, were cloned into a modified retroviral vector (RPG). 21 RPG contains the H1 promoter of RNA polymerase III, which directs the synthesis of siRNAs, and a GFP marker gene, which is utilized for the selection of transduced cells. Each of these nine constructs was introduced in Hut78 cells and GFP þ cells were then FACS-sorted for the analysis of suppression of AHI-1 expression in Hut78 cells. One construct (AHI-sh4), with specific oligonucleotides derived from N-terminal of AHI-1, was found to specifically inhibit total AHI-1 expression in stably transduced cells by 80%, as evaluated by quantitative real-time reverse transcriptase-polymerase chain reaction (Q-RT-PCR). Several transduction experiments were further performed to confirm specificity of suppression of AHI-1 expression by the AHI-sh4 vector and several stable clonal lines were subsequently isolated and shown a similar suppression of total AHI-1 (Figure 1a) . To quantify more precisely the levels of suppression of different AHI-1 isoforms, Q-RT-PCR analysis was undertaken using specific primers to detect the 3 0 end of each isoform (Figure 1b) . Interestingly, AHI-1 isoform I and II were found to be suppressed up to 80% and AHI-1 isoforms III was suppressed at 60% in transduced bulk (non-clonal) and clonal cell lines (Figure 1a) . Northern blotting showed that AHI-sh4 cells express the full-length (6.5 kb) and short AHI-1 transcripts (4.2 and 1.2 kb) at only 20% the expression levels found in parental Hut78 cells and Hut78 cells transduced with an RPG control vector (Figure 1c ). Western blot analysis using a C-terminal Ahi-1 antibody further showed reduction in the expression of full-length and shorter forms of AHI-1 (140, 110, 70 and 50 kDa) up to 80% in several AHI-sh4-transduced cell lines as compared to control cells (Figure 1c ). This result was further confirmed using an N-terminal AHI-1 antibody (data not shown). These results demonstrated successful suppression of different isoforms of a complex gene (AHI-1) using a retroviralmediated RNAi approach in a cell line model system.
Interestingly, retroviral-mediated suppression of AHI-1 also reduced autocrine production of IL-2 (40%), IL-4 (30%) and, more significantly, of TNFa (85%) in Hut78 cells as compared to control cells, as evaluated by Q-RT-PCR (Figure 2a) . However, knocking down AHI-1 expression had no effect on the autocrine production IFN-g when evaluated using the same detection method (data not shown). A significant reduction in autocrine production of TNFa in several AHI-sh4-transduced cell lines, when compared to control cells, was further detected when measured by ELISA (5.573.5 vs 6475 pg/ml, Po0.005, Figure 2b ). Western blot analysis further illustrated a significant reduction in TNFa protein expression (70%) in the AHI-sh4-1 cells as compared to control cells when cells were stimulated with TNFa in culture (Figure 2c ). In addition, control Hut78 cells showed a low basal level TNFa protein expression in the absence of TNFa stimulation, suggesting a detectable level of autocrine production of TNFa in Hut78 cells. Interestingly, reduced TNFa protein expression was also evident in the AHIsh4-1 cells in the absence of TNFa stimulation (Figure 2c ). There was no difference in reduction of AHI-1 expression in AHI-sh4-1 cells in the present or absent of TNFa (data not shown). These results were reproduced when the same experiments were conducted using other AHI-sh4-transduced cells, including AHIsh4-bulk and AHI-sh4-3 (data not shown).
Suppression of AHI-1 expression reduces growth factor independence of Hut78 cells in vitro
To investigate the effects of suppression of AHI-1 expression on the ability of Hut78 cells to proliferate autonomously in vitro, we assessed their ability to form colonies in semi-solid cultures. In the absence of growth factors, Hut78 cells with suppression of AHI-1 (AHI-sh4-1 cells) showed a significant reduction in their growth factor independence, with up to 10-fold reduction in CFC output compared to control Hut78 RPG cells (Figure 3a) . As well, as Figure 3b shows, the colonies formed by AHI-sh4-1 cells were much smaller than those of control Hut78 RPG cells. Interestingly, although addition of IL-4, TNFa or a combination of three growth factors restored colony formation from the AHIsh4-1 cells in semi-solid cultures, this was not achieved if only IL-2 was provided (Figure 3a and b) . A similar result was obtained from AHI-sh4-bulk and AHI-sh4-3 cells (data not shown).
We expanded single transduced AHI-sh4-1 cells and control cells and examined the growth kinetics of the cells obtained. Figure 4a shows that when AHI-1 expression was suppressed (AHI-sh4-1 cells), the ability to form a clone from a single cell was fourfold less than that of the controls (RPG cells) in the absence of any growth factors. In addition, most of the clones formed from cells where AHI-1 was suppressed were much smaller than those formed in control cells, consistent with the results of the CFC assays, shown in Figure 3 (Figure 4b ).
Suppression of AHI-1 expression results in a loss of the ability to induce tumors in immunodeficient mice
To investigate the effects of suppression of AHI-1 expression on the ability to induce tumors in vivo, we tested their leukemogenic potential by injecting transduced cells into NOD/SCIDb2m-immunodeficient mice. Mice injected subcutaneously with either parental Hut78 cells (2 Â 10 7 /per mouse) or control RPG cells showed local tumor formation in 10 of 10 mice within 4 weeks. The local tumors progressively enlarged and were often 1.5-2 cm in diameter by 8 weeks after injection. In contrast, no local tumors formed in mice given injections of equal numbers of AHI-sh4-bulk or clonal cell lines, after 20 weeks in 18 of 18 
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Deregulated AHI-1 expression is present in leukemic Sezary cells from patients with SS
The observation of significantly increased AHI-1 transcript levels in Hut78 cells, as well as the normalization of transforming properties of Hut78 cells in response to suppression of AHI-1 expression, further prompted us to examine primary sources of leukemic Sezary cells for evidence of aberrant AHI-1 expression. AHI-1 transcript levels were analyzed by Q-RT-PCR in CD4 þ CD7 À cells from patients with SS. As shown in Table 1 , the six patient samples studied (named as SS-2 in this study) all had typical SS presentations with erythroderma, lymphadenopathy, leukemic Sezary cells in the peripheral blood (45-75%) and a high degree of phenotypic loss of CD7 expression An oncogenic role for AHI-1 in Sezary syndrome A Ringrose et al (68-94%), consistent with reports by others. 35, 36 Three additional samples were atypical cases, with either a loss of CD7 expression or morphological Sezary cells 45%, but not both (SS-1). Q-RT-PCR analysis revealed significantly increased total AHI-1 expression in CD4 þ CD7 À Sezary cells (Po0.01) from five of six blood samples obtained from the SS-2 group, compared to cells similarly isolated from eight age-matched healthy individuals (two-to threefold; Figure 5a ). The highest expression occurred in a patient with relatively higher counts of leukemic Sezary cells (75%, patient no. 9). Elevated AHI-1 transcript levels were not found in the SS-1 group samples.
To investigate whether the altered expression of AHI-1 characteristic of primary leukemic Sezary cells might extend to an alteration in their output of different AHI-1 isoforms, additional Q-RT-PCR analyses of RNA from FACS-purified normal and Sezary cells were undertaken. As shown in Figure 5c , isoform I expression was two-to threefold greater in CD4 þ CD7 À Sezary cells from the SS-2 group. Elevated levels of isoform II transcripts were also observed in the same group, but were especially higher (44-5-fold) in patients number eight and nine. Isoform III expression was only slightly elevated in some of the SS-2 group patients by comparison to their normal blood counterparts.
Western blot analysis was then performed after protein extract preparation from the same CD4 þ CD7 À Sezary cells of the SS-2 group patient samples, with comparison to normal controls as well as Hut78 cells. This analysis revealed a modest increase in AHI-1 protein expression, compared to their normal counterparts (130 and 110 kDa, up to 2-3-fold) in the same four SS patient samples (Nos. 4 6 8 and 9), which had elevated AHI-1 transcripts. Interestingly, the levels of shorter isoforms (70 and 50 kDa) were consistently elevated (up to sixfold) in SS patient samples, with expression of the 70 kDa protein being especially high in SS patient sample nine; this 70 kDa protein was not present in patient sample six (Figure 5b) . Notably, higher levels of AHI-1 shorter isoforms were present in Hut78 cells, as reported previously. 5 These results provide evidence of splicing perturbations affecting AHI-1 expression at RNA and protein levels in primary leukemic Sezary cells.
Aberrant expression of IL-2 and TNFa occurs in leukemic cells from patients with SS
To obtain evidence of abnormal growth factor gene expression in primary Sezary cells, we further performed Q-RT-PCR analyses from FACS-purified normal and Sezary cells. Expression of IL-2, IL-4 and TNFa were detectable in normal T cells from eight healthy individuals, but these transcripts were not detected in normal CD34 þ lin À bone marrow cells ( Figure 6 , data not shown). Interestingly, IL-2 and TNFa transcript levels were elevated in the SS-2 group but not in the SS-1 group. Increased transcript levels of IL-4 were not found in any of SS patient samples studied as compared to their normal counterparts ( Figure 6 ).
Discussion
In the present study, we demonstrate for the first time, using a human CTCL cell line model system that AHI-1 is a new oncogene with strong transforming activities both in vitro and in vivo and that constitutive deregulated expression of AHI-1 mediates a multi-factor autocrine production mechanism involved in cell transformation. First, stable suppression of AHI-1 expression in Hut78 cells caused a significant suppression of multi-factorial autocrine mechanism involving IL-2, IL-4 and TNFa. Thus, there could be a direct link between elevated production of these cytokines and deregulated expression of AHI-1 in Hut78 cells. Second, AHI-1 expression appears to regulate this multi-factorial autocrine mechanism that contributes to the factor independence exhibited by Hut78 cells in vitro, as indicated by their reduced autonomous growth in the absence of growth factors on semisolid cultures and by the decreased ability of Hut78 cells to proliferate in single-cell An oncogenic role for AHI-1 in Sezary syndrome A Ringrose et al cultures when AHI-1 expression was inhibited. Third, this decrease in proliferative ability in vivo is also evident when Hut78 cells are injected into immunocompromised mice subcutaneously, with cells in which AHI-1 expression is suppressed lacking the ability to produce tumors. Thus, leukemogenic activity was dependent on the expression of AHI-1 to maintain an oncogenic phenotype in transduced Hut78 cells. In order to rule out the possible effects of doublestranded RNA-induced antiviral/interferon responses in mammalian cells, 37 we tested other AHI-1 siRNA constructs that showed no or very little suppression of AHI-1 in transduced Hut78 cells. Biological changes (as described above) were not evident in these cells (data not shown). Taken together, these findings demonstrate the importance of persisting deregulated expression of AHI-1 to the sustained autocrine production of cytokines and its in vitro and in vivo leukemic activities in the Hut78 cells.
Identification of a multi-factorial autocrine mechanism with a strong association with deregulated expression of AHI-1 in human CTCL cells raises many interesting questions about the nature of this mechanism and how this mechanism is regulated for leukemic cell transformation. Of particular note is the observation of a marked suppression of TNFa up to 85% in Hut78 cells when AHI-1 expression is inhibited, as evaluated by Q-RT-PCR, ELISA and Western blot analyses. As a result of this, CFC output and the ability to form a colony from single cells were significantly reduced. Interestingly, addition of TNFa alone to the culture system restored CFC output in Hut78 cells with the suppression of AHI-1 expression, providing evidence that AHI-1 expression may be important in mediating an autocrine loop of TNFa production. A causative relationship between AHI-1 and TNFa was further supported by detection of elevated TNFa transcript levels in primary leukemic Sezary cells from SS patients. TNFa is known to be a potent cytokine with a wide range of biological activities, including differentiation, antiviral responses and proliferation. 38 Regulation of production of TNFa is complex. It is produced mainly by activated monocytes under normal conditions and can also be produced by a number of transformed cells, suggesting that the autocrine production of An oncogenic role for AHI-1 in Sezary syndrome A Ringrose et al this factor by leukemic cells may have a pathogenic role in the progression of leukemia. 39, 40 It has been recently suggested that autocrine production of TNFa is an important mediator of histone deacetylation in leukemic cell apoptosis and that transcriptional activation of TNFa can be regulated, through, hyperacetylation of histones H3 and H4 in its promoter region. 41 Interestingly, cellular proliferation and high levels of constitutively active nuclear factor kappa B have been reported to be induced by constitutive autocrine production of TNFa in Hut78 cells. 32 More recently, a report using Microarray technology in primary human CTCL patient samples has further suggested that TNFa activation plays a critical role in the development of disease. 42 In the present study, we have also observed reduced expression of IL-2 and IL-4, evaluated by Q-RT-PCR, in Hut78 cells when AHI-1 expression was reduced. However, significant reductions of both factors were not detected by ELISA in supernatants of Hut78 cells when AHI-1 expression was suppressed (data not shown). Therefore, the relative contributions of IL-2 and IL-4 to the transformed phenotypes of Hut78 cells under the suppression of AHI-1 are unclear. Nevertheless, the finding that addition of IL-2 was not able to restore colony formation from AHI-1 suppressed cells in semisolid culture suggests that IL-2-mediated proliferation of Hut78 cells appears to be impaired when AHI-1 expression is reduced. As well, aberrant expression of IL-2 was observed in primary Sezary cells. Consistent with this finding, elevated IL-2 receptor expression has been reported to correlate well with disease states as it is highly increased in advanced CTCL as reported previously. 43, 44 Interestingly, our studies revealed that AHI-1 transcript levels were elevated in CD4 þ CD7 À cells from patients with typical SS (SS-2 group); this elevation is not found in similarly purified normal T-cell from healthy individuals or in atypical patients with a low content of leukemic Sezary cells. The highest expression of AHI-1 occurred in a patient (No. 9) with the highest percentage of Sezary cells, determined by morphology, suggesting that overexpression of AHI-1 may be restricted to the transformed Sezary cells or may occur at the later stage of disease development or in the specific subgroup of patients. This may also explain, in part, the discrepancy observed between AHI-1 transcript levels in primary SS patient samples as compared to the transcript and protein levels found in Hut78 cells, as most of the cells isolated from primary SS samples are highly heterogeneous, with a mixed normal and leukemic Sezary cell phenotype. However, we cannot exclude that Hut78 cells may also contain other mutations that may contribute to the elevated expression of AHI-1. Importantly, the present studies provide evidence of the complexity of isoforms encoded by AHI-1, and their potential to be differentially perturbed in leukemic Sezary cells. We previously demonstrated that the CTCL cell lines, Hut78 and Hut102, showed specific increases in the levels of AHI-1 transcript isoforms I and II, but not isoform III. 5 In this study, we found that primary leukemic Sezary cells showed a similar pattern of upregulated expression of AHI-1 transcript isoforms I and II, but not isoform III. Extremely high levels of isoform II were found in two SS samples (Nos. 8 and 9) and elevated protein expression of shorter AHI-1 isoforms (70 and 50 kDa) was also evident. Isoform II of AHI-1 lacks the SH3 domain and would thus be expected to encode a truncated protein with distinct properties, possibly including gain-offunction activities. The presence of elevated expression of both RNA and protein for such an entity could thus be envisaged to have significant biological consequences. Isoform III has sequences not shared by the other two isoforms, and could thus be envisaged to have potential dominant-negative activities. Interestingly, mutations in the human AHI-1 gene have recently been found to be associated with Joubert syndrome, an autosomal-recessive brain disorder. 45, 46 Abnormal cerebellar development and axonal decussation were found in individuals with point mutations in AHI-1 that generate either stop codons or amino-acid substitutions or splicing errors within the AHI-1 protein. Notably, truncating mutations are found to be the most frequent types (80%) that abolish completely or, in part, the two critical domains (WD40 and SH3) of AHI-1. 47 Therefore, it is reasonable to speculate that the truncated forms of AHI-1 generated by point mutations, or altered splice variants, are critical in the development of certain diseases, such as SS. Future experiments are in progress to fully understand the molecular mechanism, biological function and clinical value of deregulated AHI-1 expression involving in the SS development.
